Stockwatch: Can Gilead Wave Its Wand Over Antibody-Drug Conjugates?
M&A Just Transformed The Previously Checkered ADC Space
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?
